NCT00912925
MPS 1, Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
This study is being conducted to demonstrate the safety and clinical efficacy of Aldurazyme treatment in MPS I patients
All
From 5 Years
No
rhIDU (recombinant human-Alpha-L-Iduronidase), Placebo
Phase 3
Interventional
45
2000-12
2015-04-07
New York, New York, United States
Chapel Hill, North Carolina, United States
Vancouver, British Columbia, Canada
Mainz, , Germany
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields